It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disease. Accurate PD diagnosis is crucial for effective treatment and prognosis but can be challenging, especially at early disease stages. This study aimed to develop and evaluate an explainable deep learning model for PD classification from multimodal neuroimaging data. The model was trained using one of the largest collections of T1-weighted and diffusion-tensor magnetic resonance imaging (MRI) datasets. A total of 1264 datasets from eight different studies were collected, including 611 PD patients and 653 healthy controls (HC). These datasets were pre-processed and non-linearly registered to the MNI PD25 atlas. Six imaging maps describing the macro- and micro-structural integrity of brain tissues complemented with age and sex parameters were used to train a convolutional neural network (CNN) to classify PD/HC subjects. Explainability of the model’s decision-making was achieved using SmoothGrad saliency maps, highlighting important brain regions. The CNN was trained using a 75%/10%/15% train/validation/test split stratified by diagnosis, sex, age, and study, achieving a ROC-AUC of 0.89, accuracy of 80.8%, specificity of 82.4%, and sensitivity of 79.1% on the test set. Saliency maps revealed that diffusion tensor imaging data, especially fractional anisotropy, was more important for the classification than T1-weighted data, highlighting subcortical regions such as the brainstem, thalamus, amygdala, hippocampus, and cortical areas. The proposed model, trained on a large multimodal MRI database, can classify PD patients and HC subjects with high accuracy and clinically reasonable explanations, suggesting that micro-structural brain changes play an essential role in the disease course.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Calgary, Biomedical Engineering Graduate Program, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Radiology, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
2 University of Calgary, Department of Radiology, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Alberta Children’s Hospital Research Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Pediatrics and Community Health Sciences, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Hotchkiss Brain Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
3 University of Calgary, Hotchkiss Brain Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Clinical Neurosciences, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
4 University of Alberta, Neuroscience and Mental Health Institute and Department of Medicine (Neurology), Edmonton, Canada (GRID:grid.17089.37)
5 University of Calgary, Hotchkiss Brain Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Clinical Neurosciences, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Psychiatry, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Exeter, College of Medicine and Health, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024)
6 University of Calgary, Hotchkiss Brain Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Clinical Neurosciences, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); Université de Montréal, Department of Radiology, Radio-oncology and Nuclear Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136); Institut Universitaire de Gériatrie de Montréal, Centre de Recherche, Montréal, Canada (GRID:grid.294071.9) (ISNI:0000 0000 9199 9374)
7 University of Calgary, Department of Radiology, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Alberta Children’s Hospital Research Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Pediatrics and Community Health Sciences, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Hotchkiss Brain Institute, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Clinical Neurosciences, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)